Class B controlled substance with established medical cannabis access since 2018 – understanding UK drug policy, penalties, and legal CBD
| Recreational Cannabis | Illegal – Class B Drug |
| Medical Cannabis | Legal Since November 2018 |
| CBD Products | Legal Under 0.2% THC |
| Possession Penalty | Up to 5 Years Prison |
| Risk Level for Tourists | Medium – Discretionary Enforcement |
| Category | Status | Details |
|---|---|---|
| Recreational Use | Illegal | Class B controlled substance under Misuse of Drugs Act 1971 |
| Medical Cannabis | Legal | Legal since 1 November 2018 via specialist prescription only |
| Public Possession | Criminal Offence | Up to 5 years imprisonment and unlimited fine; warnings often issued for small amounts |
| Home Cultivation | Illegal | Production offence – up to 14 years imprisonment regardless of plant count |
| Retail Access | Medical Only | 30+ licensed private clinics; very limited NHS access; no recreational retail |
| Driving Limit | 2 μg/L Blood | Drug Driving (Specified Limits) Regulations 2015 – near zero tolerance |
| Tourist Access | No Access | Same criminal penalties apply; no legal purchase options for visitors |
The United Kingdom's cannabis legislation is primarily governed by the Misuse of Drugs Act 1971, which classifies cannabis as a Class B controlled substance under Schedule 1. This classification places cannabis alongside amphetamines and barbiturates, recognising it as having potential for abuse but less danger than Class A drugs such as heroin and cocaine. The Act was amended in January 2009 to upgrade cannabis from Class C back to Class B, reversing the 2004 downgrade implemented under the Labour government.
A pivotal change occurred on 1 November 2018 when the Home Office rescheduled cannabis-based products for medicinal use (CBPMs) to Schedule 2 of the Misuse of Drugs Regulations 2001. This change followed high-profile cases involving children with severe epilepsy, particularly the cases of Billy Caldwell and Alfie Dingley, whose families campaigned for medical cannabis access. The rescheduling allows specialist doctors on the General Medical Council's Specialist Register to prescribe CBPMs, though general practitioners (GPs) cannot issue these prescriptions.
The Drug Driving (Specified Limits) (England and Wales) Regulations 2015 established a near-zero tolerance limit of 2 micrograms of THC per litre of blood for driving. This limit is deliberately set at the lowest detectable threshold, reflecting government policy that any impairment from illegal drug use is unacceptable when driving. Medical cannabis patients can claim a statutory defence if their medication is prescribed and taken as directed, though they must still demonstrate fitness to drive.
In 2020, the Advisory Council on the Misuse of Drugs (ACMD) conducted a review of cannabis's legal status. Their report, published in December 2020, concluded that insufficient evidence existed to recommend rescheduling or decriminalisation of recreational cannabis. The ACMD acknowledged therapeutic potential but emphasised concerns about psychosis risk, particularly for high-potency strains. Scotland and Northern Ireland operate under the same primary legislation, though Police Scotland applies its own discretionary approach to enforcement, often favouring warnings over prosecution for minor possession offences.
| Offence | Quantity | Maximum Penalty | Enforcement Reality |
|---|---|---|---|
| Simple Possession | Personal use amounts (under 28g) | 5 years imprisonment + unlimited fine | Often cannabis warning or £90 PND; arrest unlikely for first offence |
| Repeat Possession | Second or third offence | 5 years imprisonment + unlimited fine | Formal caution or prosecution more likely; criminal record probable |
| Possession with Intent to Supply | Over 28g or dealing evidence | 14 years imprisonment + unlimited fine | Prosecution standard; custodial sentences for significant quantities |
| Supply/Dealing | Any amount | 14 years imprisonment + unlimited fine | Active prosecution; sentences 2-6 years typical for street dealing |
| Cultivation (Production) | Any plant count | 14 years imprisonment + unlimited fine | 1-9 plants for personal use: community sentence; commercial grows: 4-10 years |
| Drug Driving (THC) | Over 2 μg/L blood | 6 months imprisonment + £5,000 fine + 12 month ban | Active enforcement; roadside testing available; licence endorsement standard |
| Importation/Exportation | Any amount | 14 years imprisonment + unlimited fine | Border Force active; prosecutions standard for commercial quantities |
In practice, the Crown Prosecution Service and police forces apply significant discretion for minor cannabis offences. The Penalty Notice for Disorder (PND) scheme allows officers to issue a £90 fixed penalty for small-quantity possession without formal arrest or prosecution. First-time offenders are frequently offered a cannabis warning, which is recorded but does not constitute a criminal conviction. However, this discretion varies considerably between police forces – Metropolitan Police in London have historically pursued more prosecutions than forces in Durham or Derbyshire, where Chief Constables have publicly deprioritised minor cannabis offences.
The UK's medical cannabis framework operates as a two-tier system with markedly different accessibility between NHS and private provision. Since the November 2018 rescheduling, approximately 80,000 private prescriptions are issued annually through over 30 licensed clinics across England, Scotland, and Wales. However, NHS prescribing remains extraordinarily limited – fewer than three NHS prescriptions for unlicensed cannabis products were recorded in 2023, reflecting extreme caution from NHS trusts and CCGs regarding cost, liability, and lack of NICE guidance.
Three cannabis-based medicines have regulatory approval for specific conditions: Epidyolex (cannabidiol) for Lennox-Gastaut and Dravet syndrome epilepsy, Sativex (nabiximols) for multiple sclerosis spasticity, and Nabilone (synthetic THC analogue) for chemotherapy-induced nausea. Beyond these, unlicensed imported cannabis products from licensed suppliers including Aurora (Canada), Bedrocan (Netherlands), Khiron (Colombia), and Curaleaf UK dominate the private prescription market. These products include dried flower, oils, capsules, and vaporisation cartridges.
Project TWENTY21, launched in November 2019 by Drug Science and completed in December 2022, enrolled over 10,000 patients in the UK's largest medical cannabis observational study. Patients accessed subsidised cannabis at approximately £5 per gram (compared to typical private prices of £10-15 per gram) while contributing real-world evidence on efficacy and safety. Conditions studied included chronic pain (60% of enrolment), anxiety disorders, PTSD, multiple sclerosis, and Tourette syndrome. Preliminary data demonstrated significant patient-reported improvements in quality of life and reduction in opioid use, contributing evidence for ongoing NHS policy development.
Private consultations typically cost £50-150 for initial appointments, with follow-up reviews at £50-100. Monthly medication costs range from £150-400 depending on condition and product selection. Major UK cannabis clinics include Sapphire Medical Clinics, The Medical Cannabis Clinics, Cantourage UK, and Integro Clinics. Patients must demonstrate failed responses to at least two conventional treatments before cannabis prescription is considered appropriate.
The UK's legal CBD market has experienced explosive growth since the 2018 clarification of CBD's lawful status. The Food Standards Agency (FSA) implemented Novel Food regulations requiring all CBD ingestibles to obtain authorisation by March 2021 (deadline subsequently extended). As of 2024, over 12,000 CBD products have applications under review, with several hundred having received full approval. High street retailers including Holland & Barrett, Boots, and Superdrug now stock CBD oils, capsules, and topicals, alongside dedicated CBD boutiques in London and major cities.
The illicit cannabis market remains substantial despite medical legalisation. Home Office estimates suggest approximately 2.6 million UK adults used cannabis in 2023, with the vast majority obtaining products from illegal sources. Street prices average £10 per gram for standard flower, £12-15 for higher-quality strains. Domestic cultivation, particularly Albanian-organised cannabis farms, continues to supply significant market share despite law enforcement operations including National Crime Agency and regional organised crime units.
Cannabis has a complex cultural history in Britain stretching back to hemp cultivation for naval rope in the Tudor period. However, recreational cannabis use became culturally significant only in the 20th century, initially associated with jazz musicians and Caribbean immigrant communities in the 1950s and 1960s. The 1967 arrest of Rolling Stones members Mick Jagger and Keith Richards for cannabis possession brought the drug into mainstream public consciousness, while the subsequent appeal and reduced sentences highlighted establishment discomfort with harsh drug penalties.
The 1971 Misuse of Drugs Act created the classification system still in use today, though cannabis's position within it has fluctuated. The Brixton Cannabis Warning Pilot (2001-2002) under Metropolitan Police Commander Brian Paddick demonstrated that deprioritisation could work without increasing use, leading to the 2004 downgrade to Class C. However, media-driven concerns about "skunk" (high-THC varieties) and psychosis links prompted the 2009 reclassification to Class B under Home Secretary Jacqui Smith, against the advice of the ACMD, whose chair Professor David Nutt was subsequently dismissed for publicly criticising the decision.
Contemporary UK cannabis culture centres on events like the annual Cannabis March in London, held each May since 1998, and the UK Cannabis Social Club movement advocating for legalisation. Medical cannabis campaigns, particularly the United Patients Alliance and the work of journalist Peter Reynolds, have shifted public discourse toward therapeutic acceptance. Polling consistently shows majority support for medical cannabis (78-85%) and plurality support for recreational legalisation (45-52%), though no major political party currently advocates full legalisation – the Liberal Democrats support decriminalisation while Labour and Conservatives maintain current policy frameworks.
No. Cannabis is a Class B controlled drug under the Misuse of Drugs Act 1971. Possession is a criminal offence carrying up to 5 years imprisonment for both residents and tourists. In practice, police often issue warnings or Penalty Notices for Disorder for small personal amounts, but this is entirely discretionary. Do not assume lenient enforcement.
Yes, since November 2018 specialist doctors (not GPs) can legally prescribe cannabis-based medicines. Access is predominantly via private clinics — NHS prescribing remains very limited. Conditions covered include epilepsy (Epidyolex), multiple sclerosis spasticity (Sativex), chemotherapy-induced nausea, and chronic pain. Approximately 80,000 private prescriptions are issued annually.
Under the Misuse of Drugs Act: possession carries up to 5 years imprisonment and an unlimited fine. Supply or intent to supply carries up to 14 years. In practice, first-time small-quantity possession often results in a warning or Penalty Notice for Disorder of £90. Repeat offences or aggravating circumstances increase prosecution likelihood significantly.
Yes. CBD products are legal in the UK provided they contain less than 0.2% THC and are produced from approved hemp strains. The UK Food Standards Agency regulates CBD as a Novel Food — products require FSA approval to be legally sold as food supplements. CBD flower remains in a legal grey area as it visually resembles controlled cannabis.
Project TWENTY21 was the UK’s largest observational medical cannabis study, run by Drug Science. It enrolled over 10,000 patients between 2019 and 2022, collecting real-world efficacy data for chronic pain, PTSD, anxiety, and multiple sclerosis. The study provided foundational evidence supporting expanded UK medical cannabis access and informed NICE guidance development.